Terms: = Prostate cancer AND TAL1, TCL5, 6886, ENSG00000162367, SCL, P17542, tal-1
18 results:
1. Separated collaborative learning for semi-supervised prostate segmentation with multi-site heterogeneous unlabeled MRI data.
Xu Z; Lu D; Luo J; Zheng Y; Tong RK
Med Image Anal; 2024 Apr; 93():103095. PubMed ID: 38310678
[TBL] [Abstract] [Full Text] [Related]
2. The link between bone-derived factors osteocalcin, fibroblast growth factor 23, sclerostin, lipocalin 2 and tumor bone metastasis.
Martiniakova M; Mondockova V; Biro R; Kovacova V; Babikova M; Zemanova N; Ciernikova S; Omelka R
Front Endocrinol (Lausanne); 2023; 14():1113547. PubMed ID: 36926025
[TBL] [Abstract] [Full Text] [Related]
3. Multimodal Contrastive Supervised Learning to Classify Clinical Significance MRI Regions on prostate cancer.
Gutierrez Y; Arevalo J; Martinez F
Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():1682-1685. PubMed ID: 36086464
[TBL] [Abstract] [Full Text] [Related]
4. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.
Tang F; Xu D; Wang S; Wong CK; Martinez-Fundichely A; Lee CJ; Cohen S; Park J; Hill CE; Eng K; Bareja R; Han T; Liu EM; Palladino A; Di W; Gao D; Abida W; Beg S; Puca L; Meneses M; de Stanchina E; Berger MF; Gopalan A; Dow LE; Mosquera JM; Beltran H; Sternberg CN; Chi P; Scher HI; Sboner A; Chen Y; Khurana E
Science; 2022 May; 376(6596):eabe1505. PubMed ID: 35617398
[TBL] [Abstract] [Full Text] [Related]
5. Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo.
Elango R; Vishnubalaji R; Manikandan M; Binhamdan SI; Siyal AA; Alshawakir YA; Alfayez M; Aldahmash A; Alajez NM
Sci Rep; 2019 Sep; 9(1):13696. PubMed ID: 31548560
[TBL] [Abstract] [Full Text] [Related]
6. Contemporary national trends in prostate cancer risk profile at diagnosis.
Fletcher SA; von Landenberg N; Cole AP; Gild P; Choueiri TK; Lipsitz SR; Trinh QD; Kibel AS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):81-87. PubMed ID: 31235801
[TBL] [Abstract] [Full Text] [Related]
7. The human oncogene scl/tal1 interrupting locus (STIL) promotes tumor growth through MAPK/ERK, PI3K/Akt and AMPK pathways in prostate cancer.
Wu X; Xiao Y; Yan W; Ji Z; Zheng G
Gene; 2019 Feb; 686():220-227. PubMed ID: 30453068
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptional regulatory networks in human lung adenocarcinoma.
Meng X; Lu P; Bai H; Xiao P; Fan Q
Mol Med Rep; 2012 Nov; 6(5):961-6. PubMed ID: 22895549
[TBL] [Abstract] [Full Text] [Related]
9. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract] [Full Text] [Related]
10. A method to quantify and compare clinicians' assessments of patient understanding during counseling of standardized patients.
Farrell MH; Kuruvilla P; Eskra KL; Christopher SA; Brienza RS
Patient Educ Couns; 2009 Oct; 77(1):128-35. PubMed ID: 19380210
[TBL] [Abstract] [Full Text] [Related]
11. Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue.
Hwang SH; Rait A; Pirollo KF; Zhou Q; Yenugonda VM; Chinigo GM; Brown ML; Chang EH
Mol Cancer Ther; 2008 Mar; 7(3):559-68. PubMed ID: 18347143
[TBL] [Abstract] [Full Text] [Related]
12. MAP17 overexpression is a common characteristic of carcinomas.
Guijarro MV; Leal JF; Fominaya J; Blanco-Aparicio C; Alonso S; Lleonart M; Castellvi J; Ruiz L; Ramon Y Cajal S; Carnero A
Carcinogenesis; 2007 Aug; 28(8):1646-52. PubMed ID: 17426052
[TBL] [Abstract] [Full Text] [Related]
13. Validation of sternal skin conductance for detection of hot flashes in prostate cancer survivors.
Hanisch LJ; Palmer SC; Donahue A; Coyne JC
Psychophysiology; 2007 Mar; 44(2):189-93. PubMed ID: 17343702
[TBL] [Abstract] [Full Text] [Related]
14. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract] [Full Text] [Related]
15. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract] [Full Text] [Related]
16. Quality of life of men treated with brachytherapies for prostate cancer.
Lev EL; Eller LS; Gejerman G; Lane P; Owen SV; White M; Nganga N
Health Qual Life Outcomes; 2004 Jun; 2():28. PubMed ID: 15198803
[TBL] [Abstract] [Full Text] [Related]
17. [prostate specific antigen doubling time in prostate cancer before treatment and in refractory status].
Nakata S; Takezawa Y; Kobayashi M; Kuribara H; Matumoto K; Kosaku N; Suzuki T; Yamanaka H
Nihon Rinsho; 1998 Aug; 56(8):2026-30. PubMed ID: 9750501
[TBL] [Abstract] [Full Text] [Related]
18. [Serum copper and zinc levels in patients with malignant neoplasm of the urogenital tract].
Sanada S; Ogura K; Kiriyama T; Yoshida O
Hinyokika Kiyo; 1985 Aug; 31(8):1299-316. PubMed ID: 4083194
[TBL] [Abstract] [Full Text] [Related]
